Julia Wulfkuhle

George Mason University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index8.7kcitations338works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Biosensing Techniques and Applications(62), HER2/EGFR in Cancer Research(59), Monoclonal and Polyclonal Antibodies Research(57), Advanced Breast Cancer Therapies(56), Cancer Immunotherapy and Biomarkers(47)

Publications338 total

Supplementary Data1 from The Impact of <i>JAK1</i> Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer
2025Open Access
Abstract C051: Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omics data and organoid studies
Molecular Cancer Therapeutics·2025
Supplementary Tables 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
2025Open Access
Supplementary Figure 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
2025Open Access
Data from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
2025Open Access
The Impact of <i>JAK1</i> Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer
Clinical Cancer Research·2025
The impact of JAK1 mutations and MHC-I expression on response to immune checkpoint inhibition in endometrial cancer
Gynecologic Oncology·2025
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
Clinical Cancer Research·2025· 3 citedOpen Access
Abstract P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant Setting
Clinical Cancer Research·2025
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide
Clinical Cancer Research·2025
Ovarian cancer proteomic biomarkers for pembrolizumab response
Gynecologic Oncology Reports·2025Open Access
Abstract 2637: Investigation of cell shape, focal adhesion, and cytoskeletal changes induced by SIAH inhibition in malignant human cancer cell lines
Cancer Research·2025
Abstract 5762: RPPA kinomic profiling of a tumor eradication phenotype induced by SIAH inhibition, a major tumor vulnerability in the EGFR/HER2/RAS signaling pathway, in late-stage and metastatic human cancer cell lines
Cancer Research·2025
T-type calcium channels regulate medulloblastoma and can be targeted for therapy
Journal of Neuro-Oncology·2025Open Access
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit
Molecular & Cellular Proteomics·2024Open Access
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
UNC Libraries·2024Open Access
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
npj Breast Cancer·2024· 7 citedOpen Access
Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models
Cancer Research·2024
Table S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
2024Open Access
Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
2024Open Access
page 1 of 17Next →

Frequent Co-authors

Emanuel F. Petricoin(26), Lance A. Liotta(25), Emanuel F. Petricoin(16), Rosa I. Gallagher(13), Virginia Espina(12), Laura J. Esserman(8), Jianghong Deng(6), Christina Yau(6), Denise M. Wolf(6), Lamorna Brown Swigart(6), Gillian L. Hirst(6), Angela DeMichele(6), Valerie Calvert(5), Douglas Yee(5), Nola M. Hylton(5), Smita Asare(4), Hope S. Rugo(4), Donald A. Berry(4), Laura van ‘t Veer(4), Mariaelena Pierobon(4)